Cargando…
Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy—Kynurenines Are Important Players
Neurodegeneration is one of the driving forces behind the pathogenesis of multiple sclerosis (MS). Progression without activity, pathopsychological disturbances (cognitive impairment, depression, fatigue) and even optic neuropathy seems to be mainly routed in this mechanism. In this article, we aim...
Autores principales: | Sandi, Dániel, Fricska-Nagy, Zsanett, Bencsik, Krisztina, Vécsei, László |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201043/ https://www.ncbi.nlm.nih.gov/pubmed/34198750 http://dx.doi.org/10.3390/molecules26113423 |
Ejemplares similares
-
Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives
por: Biernacki, Tamás, et al.
Publicado: (2020) -
Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations
por: Biernacki, Tamás, et al.
Publicado: (2022) -
Epidemiology of multiple sclerosis in Central Europe, update from Hungary
por: Biernacki, Tamás, et al.
Publicado: (2020) -
Kynurenines, neurodegeneration and Alzheimer’s disease
por: Kincses, Zsigmond Tamas, et al.
Publicado: (2010) -
The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary
por: Biernacki, Tamás, et al.
Publicado: (2022)